• Wondering if Cigna Group at around US$275.64 is a bargain or a value trap? This article walks through what that price could actually represent for you.
• The stock is down 16.1% over the last year, with a 1.1% decline in the last week and a 1.2% decline year to date, but it has a 2.0% return over the last 30 days that hints at shifting sentiment.
• Recent coverage has focused on how Cigna Group fits into the broader US healthcare insurance space, including its scale in medical benefits and its position in pharmacy benefits management, which often influences how investors think about long term growth versus regulatory risk. Commentary has also highlighted ongoing cost pressures and competition in managed care, factors that can quickly reshape expectations around what investors are willing to pay for the stock.
• Cigna Group currently has a value score of 6/6. The rest of this article will walk through how traditional valuation methods arrive at that result and will also introduce a more complete way to think about value at the end.

Approach 1: Cigna Group Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model looks at the cash Cigna Group is expected to generate in the future and discounts those dollar amounts back to what they could be worth today. It is essentially asking what a rational buyer might pay now for all those future cash flows.

Cigna Group last reported trailing twelve month free cash flow of about $8.0b. Analysts and extrapolated estimates used in this 2 Stage Free Cash Flow to Equity model project free cash flow of $10.2b by 2030, with a path that includes yearly estimates such as $9.1b in 2026 and around $10.7b in 2035, all in dollar terms. Simply Wall St discounts each of these projected cash flows back to today using its chosen rate to arrive at a present value.

Putting those discounted cash flows together gives an estimated intrinsic value of about $891.23 per share. Compared with the recent share price near $275.64, the DCF output suggests the stock is 69.1% undervalued on this set of assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Cigna Group is undervalued by 69.1%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Approach 2: Cigna Group Price vs Earnings

For a profitable company, the P/E ratio is a useful quick check on what you are paying for each dollar of current earnings. It links directly to what the business is earning today and is easy to compare with other companies in the same space.

In general, higher growth expectations and lower perceived risk can justify a higher P/E ratio, while slower growth or higher risk tend to line up with a lower, more conservative multiple. That is why a single “normal” P/E is hard to define without context.

Cigna Group currently trades on a P/E of 12.2x, compared with a Healthcare industry average of about 24.1x and a peer group average of 48.83x. Simply Wall St’s Fair Ratio for Cigna Group is 29.80x, which is its proprietary view of what a reasonable P/E might look like after considering factors such as earnings growth, profit margins, industry, market cap and key risks.

This Fair Ratio can be more informative than a simple comparison with peers or the broad industry because it adjusts for those company specific characteristics instead of assuming all insurers deserve the same multiple. With a current P/E of 12.2x versus a Fair Ratio of 29.80x, the multiple based view points to the shares trading below that implied level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Cigna Group Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St’s Community page let you attach a clear story about Cigna Group to the numbers by linking your view of its future revenue, earnings and margins to a financial forecast and a fair value that updates as fresh news or earnings arrive. For example, one Cigna Group Narrative might echo the more optimistic analyst view with a fair value near US$378.00 based on confidence in specialty pharmacy growth and margin expansion. A more cautious Narrative might sit closer to US$290.00 if you place greater weight on regulatory and PBM risks. By comparing any Narrative fair value you agree with to the current share price, you can decide for yourself whether the stock looks closer to an opportunity or something to avoid.

Do you think there's more to the story for Cigna Group? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.